General Information of Drug (ID: DMF93U1)

Drug Name
Etilevodopa Drug Info
Synonyms
LDEE; ND-0601; TV-1203; Levodopa-ethyl-ester; Levodopa prodrug (transdermal, Parkinson's disease); Levodopa prodrug (transdermal, Parkinson's disease), NeuroDerm; L-DOPA prodrug (transdermal, Parkinson's disease), NeuroDerm; Levodopa ester, (transdermal, Parkinson's disease), NeuroDerm
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
170345
ChEBI ID
CHEBI:135971
CAS Number
CAS 37178-37-3
TTD Drug ID
DMF93U1
INTEDE Drug ID
DR1796

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DME
Drug Status:
Approved Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [3]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [4]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [5]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [6]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [7]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [8]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [9]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [10]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [11]
Propranolol DM79NTF Angina pectoris BA40 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010329)
2 Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
3 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
4 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
5 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
6 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
7 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
9 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
10 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
11 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
12 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.